Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma (Q58415142)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12060117%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

title

Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12060117%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

0 references

1 reference

1 reference

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12060117%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

2

Donna Neuberg

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12060117%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

author name string

Jonathan W Friedberg

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12060117%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

John G Gribben

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12060117%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

David C Fisher

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12060117%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Christine Canning

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12060117%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Margaret Koval

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12060117%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Christine M Poor

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12060117%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Luke M Green

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12060117%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

John Daley

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12060117%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Robert Soiffer

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12060117%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Arnold S Freedman

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12060117%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

language of work or name

English

0 references

publication date

1 June 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12060117%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Haematology

9 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12060117%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

volume

117

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12060117%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

page(s)

828-834

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12060117%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12060117%20AND%20SRC:MED&resulttype=core&format=json

Phase II trial of outpatient interleukin-2 in malignant lymphoma, chronic lymphocytic leukemia, and selected solid tumors

9 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03535.X

Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03535.X

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03535.X

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03535.X

Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03535.X

Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03535.X

Interleukin 2 signaling involves the phosphorylation of Stat proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03535.X

Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03535.X

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03535.X

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03535.X

Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03535.X

Interleukin-2: inception, impact, and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03535.X

10.1046/J.1365-2141.2002.03535.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12060117%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1 reference